"lack of proper protective gear and the overall situation in Indonesia". The vast majority of those infected were protected from severe symptoms and recovered without hospitalization. A Hong Kong 2022 study of the BA.2 Omicron variant comparing CoronaVac with BNT162b2 (Pfizer) found effectiveness of 32.4% and 41.4% (respectively) in preventing infections with two doses, and 41.6% versus 50.9% (respectively) in preventing infections with three doses. Another Hong Kong study of the BA.2 Omicron variant comparing CoronaVac with BNT162b2 for adults over age 60 found effectiveness of 69.9% versus 89.3% (respectively) in preventing severe disease or death with two doses, and 97.9% for both vaccines with three doses. Authorizations The World Health Organization (WHO) validated the Sinovac-CoronaVac COVID-19 vaccine for emergency use on 1 June 2021. The recommendation was given with limited evidence at the time of approval for groups other than healthy adults. The WHO Strategic Advisory Group of Experts expressed high level of confidence in the efficacy of the vaccine for adults, moderate confidence in the efficacy for older adults and individuals with comorbidities, moderate confidence in its safety for adults and low confidence in its safety for the elderly and individuals with comorbidities. In late August 2020, China approved CoronaVac for emergency use to vaccinate high-risk groups such as medical staff. In early February, China approved CoronaVac for general use. On 5 June 2021, China approved CoronaVac for emergency use with children and adolescents for 3–17 years old. In January 2021, Bolivia authorized use of CoronaVac. In April, Panama approved emergency use of Coronavac. On 4 May, the EMA's human medicines committee (CHMP) started a rolling review of CoronaVac. In June, Bangladesh approved Coronavac for emergency use. Society and culture Economics As of 7 July 2021, CoronaVac is the most widely used COVID-19 vaccine in the world, with 943 million doses delivered globally. In July, Sinovac signed advanced purchase agreements with GAVI to supply COVAX with 50 million doses in the third quarter of 2021 and up to a total of 380 million doses by the first half of 2022. Asia In January, Azerbaijan launched its vaccination campaign with CoronaVac. It purchased 4 million doses from Turkey and 5 million doses from China. In May, Armenia received 100,000 doses from China. In February, Cambodia approved Coronavac for emergency use and started vaccinations in March. By July, the country had received 10.5 million doses. In October, Saudi Arabia signed